A new vaccine to enhance immune response against HPV-related cancers
Highly stable mini-circRNA vaccine with maximally activated and long-lasting T cells for HPV-related cancer combination immunotherapy
This study is working on a new mini-vaccine that helps your immune system better fight cancers linked to HPV, like anal and cervical cancers, aiming to make treatments more effective and safer for patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ampedrna Biosciences LLC NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10921006 on NIH RePORTER |
What this research studies
This research focuses on developing a mini-circRNA vaccine aimed at enhancing the immune response specifically against cancers related to human papillomavirus (HPV), such as anal and cervical cancers. The approach involves creating a vaccine that can stimulate T cells to recognize and attack cancer cells more effectively. By utilizing innovative immunotherapy techniques, the goal is to improve the efficacy of existing treatments and provide a safer, more cost-effective option for patients. This vaccine could potentially be used at various stages of cancer, making it a versatile treatment option.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with HPV-related cancers, particularly those who may not have responded well to existing treatments.
Not a fit: Patients with non-HPV related cancers or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that significantly improves the immune response against HPV-related cancers, potentially reducing cancer incidence and mortality.
How similar studies have performed: While there have been successful immunotherapy approaches in cancer treatment, this specific mini-circRNA vaccine approach is relatively novel and has not been extensively tested.
Where this research is happening
Richmond, United States
- Ampedrna Biosciences LLC — Richmond, United States (Active)
Researchers
- Principal investigator: Parry, Gordon — Ampedrna Biosciences LLC
- Study coordinator: Parry, Gordon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.